Globe Newswire

BGHL (GBP): NAV(s) Jun 10, 2024 01:30AM

                                      BOUSSARD & GAVAUDAN HOLDING LIMITED

Ordinary Shares

The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

Close of business 07 Jun 2024.

Estimated NAV

  Euro Shares Sterling Shares Estimated NAV €    28.0982 £    25.1939 Estimated MTD return      0.34 %      0.36 % Estimated YTD return      2.00 %      2.54 % Estimated ITD return ... (continue reading...)

BGHL (EUR): NAV(s) Jun 10, 2024 01:30AM

                                      BOUSSARD & GAVAUDAN HOLDING LIMITED

Ordinary Shares

The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

Close of business 07 Jun 2024.

Estimated NAV

  Euro Shares Sterling Shares Estimated NAV €    28.0982 £    25.1939 Estimated MTD return      0.34 %      0.36 % Estimated YTD return      2.00 %      2.54 % Estimated ITD return ... (continue reading...)

Viridien launches new brand to accelerate growth as an advanced technology company Jun 10, 2024 01:30AM

Paris, France – June 10, 2024

Viridien, formerly CGG, today launched its new brand at the 2024 EAGE Annual Conference in Oslo, marking the next stage in its strategic growth as an Advanced Technology, Digital and Earth Data company.

Since this strategy was announced in 2018, the company has divested its data acquisition activities and increased the differentiation in its core businesses of Geoscience, Earth Data and Sensing & Monitoring. New Businesses are... (continue reading...)

Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization Jun 10, 2024 01:05AM

• The test uses highly sensitive PCR technology, requiring only a single nasal-swab sample to provide rapid, accurate qualitative detection and differentiation among four of the most prevalent respiratory viruses for which differential diagnosis can drive appropriate treatment.
• Enables healthcare professionals to make confident clinical decisions and promptly determine appropriate treatment, with definitive results reported in just 20 minutes.
• Expands Roche’s extensive... (continue reading...)

IMCD Italy expands its Pharmaceuticals presence with the acquisition of Selechimica Jun 10, 2024 01:00AM

ROTTERDAM, The Netherlands (10 June 2024) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Italy has signed an agreement to acquire 100% of the shares in Selechimica S.R.L. (“Selechimica”), an Italian distributor in the pharmaceutical industry.

Headquartered in Milan, Italy, Selechimica distributes an extensive portfolio of Active Pharmaceutical Ingredients (APIs). With 3 employees, Selechimica... (continue reading...)